Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
What Lupin files
- Updates148
- Others107
- Investor Meet34
- Important19
- PPTs8
- Board Meeting8
Lupin received U.S. FDA approval for Modafinil Tablets (100 mg & 200 mg) to treat excessive sleepiness. This key business development targets a market with estimated annual U.S. sales of USD 7.07 Cr.
Lupin received an independent "Strong" ESG rating of Crisil ESG 69 (Core ESG 65) for FY26 from Crisil ESG Ratings. The assessment, based on public data, places the company in the 'Strong' category for its environmental, social, and governance performance.
Lupin received an independent ESG rating of '60', categorized as 'Adequate', from ESG Risk Assessments & Insights. This assessment was conducted without the company's direct engagement.
Lupin received U.S. FDA final approval for its generic Pitolisant Tablets (4.45 mg & 17.8 mg), bioequivalent to Wakix®. This expands the company's product portfolio for the US market.
Lupin secured U.S. FDA approval for Sodium Zirconium Cyclosilicate Oral Suspension, a drug for hyperkalemia. The reference product had estimated annual sales of USD 56.8 Cr, indicating a significant market opportunity.